Dealmakers adjusted to the new landscape of remote work and navigating a global health crisis in 2020. These challenges created opportunities to examine new approaches in M&A, licensing, and collaborations. How are companies making decisions on acquisitions and valuation? What is on the horizon for the second half of 2021? Top-performing industry deal-makers will explore the impact market forces will have on pharmaceutical and biotech companies as they strive to make the next big deal.